Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease

Wuhan General Hospital of Guangzhou Military Command

Status and phase

Completed

Phase 4

Conditions

Left Ventricular Mass

Coronary Artery Disease

Type 2 Diabetes

Treatments

Drug: alpha-lipoic acid

Study type

Interventional

Funder types

Other

Identifiers

NCT01877590

2013Wze029

Details and patient eligibility

About

Cardiovascular complications account for the highest mortality in type 2 diabetic patients, mainly due to coronary artery disease (CAD). Most of the attention in treating CAD in type 2 diabetes is understandably directed toward treating coronary artery conditions. However there are other treatable culprits in these patients.

Left ventricular hypertrophy (LVH) is widespread in type 2 diabetic patients with CAD, even in the absence of hypertension. It is a strong predictor of cardiovascular events and all-cause mortality. Regression of LVH has been associated with an improved prognosis, independent of change in blood pressure (BP). Therefore, cardiovascular events and mortality in type 2 diabetes with CAD might will be reduced if the investigators can find novel therapies to regress LVH.

Alpha-lipoic acid reduces oxidative stress which then regresses LVH. Alpha-lipoic acid can improve endothelial function in diabetic conditions. Hence, the main aim of this study was to assess whether alpha-lipoic acid could regress LVM in type 2 diabetic patients with CAD.

Enrollment

66 patients

Sex

All

Ages

40 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Type 2 diabetes
CAD
Left ventricular hypertrophy
HbA1c below 7.0%
blood pressure <130/80 mmHg

Exclusion criteria

Patients were excluded if they were currently alpha-lipoic acid for one year, had a previous adverse reaction to alpha-lipoic acid.
hey were also excluded if they had renal and liver dysfunction, heart failure, or malignancy, or were unable to give informed consent.
Patients with contraindications to cardiac magnetic resonance (CMR) (pacemakers, claustrophobia) were also excluded, as were pregnant or lactating women.